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Abstract
Introduction The main purpose of this study was to
determine whether the optic cups of tamoxifen users
and anastrozole users differ in size, with the cups of the
tamoxifen users being smaller.
Methods Optic nerve head (ONH) topography was
measured using a commercially available, confocal
scanning laser ophthalmoscope for three populations
of amenorrheic women ages 40–69 years: subjects
using (1) tamoxifen (20 mg/day) or (2) anastrozole
(1 mg/day) for £ 2 years as adjuvant therapy after
successful primary treatment for breast cancer, and (3)
control subjects with no breast cancer histories and not
using any hormonal medication. All subjects had
excellent visual acuity and healthy eyes, based on
conventional photographic assessment.
Results The cup volumes of the tamoxifen users were
shown to be signiﬁcantly smaller than the cup volumes
of the anastrozole users, which were indistinguishable
from normal. Because the cup volumes of the tamox-
ifen users decreased markedly with age at about
50 years and because anastrozole is indicated only for
post-menopausal women, comparisons were reassessed
for subjects older than 50 years. For these subjects, the
cup volumes of the tamoxifen users averaged less than
half of the volumes for each of the other two subject
groups, and signiﬁcant between-group differences
existed in both the lateral (cup area) and axial (cup
depth) directions. In contrast, any between-group dif-
ferences at the ONH margin were small and not
signiﬁcant.
Conclusions The results of this study suggest that the
ONH be assessed biomorphometrically for tamoxifen
users reporting visual change that cannot be attributed
to non-tamoxifen causes. The ability of modern intra-
ocular imaging techniques to reveal anatomic change
on the order of tens of microns may be useful for
assessing tamoxifen-induced effects occurring simulta-
neously elsewhere in the brain, particularly since the
presence of small cups is consistent with the possibility
of tamoxifen-induced astrocytic swelling.
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Introduction
Selective estrogen receptor modulators (SERMS) and
aromatase inhibitors are the two major classes of
medications used in the United States as adjuvant
endocrine therapy for early-stage, hormone-receptor-
positive breast cancer. Of the SERMS that are FDA-
approved for this purpose [1], tamoxifen has been the
most widely used, and for several decades it has been
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DOI 10.1007/s10549-006-9486-3prescribed extensively for women of all ages [2]. The
ﬁrst aromatase inhibitor to be FDA-approved for
early-stage breast cancer was anastrozole (Arimidex
 ),
in 2002 [2]. However, because aromatase inhibitors do
not block estrogen production adequately for pre-
menopausal women [3], they are indicated for use by
post-menopausal women only [4], for whom estrogen
production is entirely non-ovarian [5]. Initial reports
indicate that anastrozole is more effective than
tamoxifen at preventing cancer recurrence [6, 7]. Thus,
anastrozole now is being recommended for many wo-
men who would have been prescribed tamoxifen sev-
eral years ago [8]. Because the use of aromatase
inhibitors is likely to continue to increase and because
the use of tamoxifen may become progressively more
restricted to younger women, the potential side effects
of anastrozole need to be evaluated, and the inﬂuence
of age on tamoxifen side-effects needs to be closely
examined.
Of all the documented or putative effects of
tamoxifen on the visual system [9], tamoxifen reti-
nopathy may be the most widely known. However,
tamoxifen retinopathy is uncommon [10] and possibly
cumulative-dose-dependent [11]. In contrast, Eisner
et al. [12] found that short-term tamoxifen users (i.e.,
£2 years of use) often have smaller optic cups than
age-matched female control subjects, in a study of
women who had been selected for the absence of any
overt eye disease. This result was consistent with the
possibility that tamoxifen often causes a subclinical
degree of swelling at the optic cup, particularly since
tamoxifen is a potent blocker (at least in culture) of
swelling-activated chloride channels [13, 14], such as
those in astrocytes [15, 16], and astrocytes are the
predominant glial cell in the cup [17, 18]. If tamoxifen
indeed causes optic-cup swelling via its ability to
block swelling-activated chloride channels, the cup
sizes of anastrozole users would be expected to more
closely resemble those of female control subjects than
those of tamoxifen users. The present study tested this
prediction.
Because of changing trends in adjuvant breast can-
cer treatment, the present study also assessed the effect
of age on optic nerve head (ONH) parameters. The
results support the inference that tamoxifen usage can
lead to small cups, although apparently mainly for
women older than about 50 years. All measurements
for this study were obtained using confocal scanning
laser ophthalmoscopy with the Heidelberg Retina To-
mograph II (HRT). This commercial instrument was
introduced in 1999 for routine clinical use, but until
now, it has been used mainly to assess glaucoma and
related conditions.
Methods
Subjects
Three groups of amenorrheic women ages 40–69 years
old were recruited for this study: (1) women using the
standard dose of 20 mg tamoxifen daily as adjuvant
therapy for breast cancer for at least 4 months but no
longer than 2 years, (2) women using the standard dose
of 1 mg anastrozole daily as adjuvant therapy for
breast cancer for at least 4 months but no longer than
2 years, and (3) women not using any hormonally
acting medications. This third group served as an
approximately age-matched control group. The 2-year
duration-of-use requirement was based on results from
several studies of vision [19, 20] and the eye [12]
indicating that short- versus long-term tamoxifen use
can be distinguished operationally using a 2-year cut-
off. The 4-month duration-of-use requirement was in-
cluded to help ensure that the medications had time to
act and that the body’s response had a chance to sta-
bilize [21, 22].
All tamoxifen and anastrozole users had completed
primary treatment for breast cancer, and all were fully
active and able to perform their daily pre-cancer
activities without restriction. None of the control sub-
jects had positive breast cancer histories or had previ-
ously used breast cancer medication for any purpose.
Similarly, none of the tamoxifen users had previously
used a hormonally acting breast cancer medication
other than tamoxifen, and none of the anastrozole
users had previously used a hormonally acting breast
cancer medication other than anastrozole. In addition,
none of the subjects in any group had ever used the
SERM raloxifene.
With one exception, all analyses for this report are
based on data from subjects who had been amenor-
rheic for at least 6 months at the time of testing. The
one exception is an analysis comparing data from
control subjects with data from an additional group of
women (the fourth subject group overall) who met the
same eligibility criteria as the control group, except for
the absence of menses.
All subjects, regardless of group, met a rigorous set
of eligibility criteria for excellent ocular health in order
to reduce the roles of confounding factors that could
complicate the data. These are the same criteria we
have used previously for several types of studies [12,
19, 23]. These criteria are: (1) 20/20 or better visual
acuity in one eye and 20/25 or better visual acuity in
the other eye, (2) no evidence or suspicion of eye
disease on undilated direct ophthalmoscopic examina-
tion and on subsequent evaluation of individuals’
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123stereoscopic color fundus and ONH photographs by a
glaucoma specialist (author JRS) who was masked
from identifying subject information, (3) no history of
eye disease or ocular hypertension, (4) no diabetes, (5)
intraocular pressure (IOP) £22 mmHg on Goldmann
applanation and no between-eye IOP difference
>2 mm Hg, (6) no myopia >5 diopters, (7) no use of
any medication (other than tamoxifen) known to affect
vision, (8) no history of ocular surgery, and (9) normal
color vision (i.e., no worse than a single minor trans-
position error on the D-15 test conducted under Mac-
beth illumination). There was no suggestion of
papilledema for any subject (as for criterion #2).
Demographic data for eligible subjects with usable
HRT data (see second paragraph of Procedures) are
given in Table 1 for each of the three amenorrheic
subject groups plus the additional group comprised of
women without breast cancer histories and still expe-
riencing menses. The mean ages of the tamoxifen users
were slightly lower than the mean ages of the anas-
trozole users and amenorrheic control subjects possibly
because some tamoxifen users were not menopausal
despite being amenorrheic [24]. For reference, the
median age of natural menopause in American society
is 51 years [25].
All subjects were unpaid volunteers. Recruitment
methods have been described previously [19]. All
subjects were Caucasian, except for one Asian subject
still experiencing menses. After being informed of the
nature and possible consequences of the study, all
subjects gave written informed consent to participate
in this study. The study protocol adhered to the tenets
of the Declaration of Helsinki and was approved by the
OHSU Institutional Review Board and the OHSU
Cancer Institute. For each subject, HRT data and IOP
measurements were obtained at the same testing
session. Subject recruitment and assessment lasted
several years, until usable HRT data had been col-
lected for 20 eligible anastrozole users.
Procedures
ONH scans were obtained using the HRT II according
to standard techniques, after which a contour line is
drawn on the average of three rapid-succession scans to
deﬁne the margin of the ONH (i.e., of the optic disk)
[26]. Stereo color photographs of the ONH were used
to assist with contour-line placement, and extensive use
was made of the ability of the HRT II software to
rotate images in three dimensions. Contour lines were
drawn with the grader masked from all other subject
information, including subject group and age. Addi-
tional details have been presented previously [12].
However, we had previously placed the contour line as
close as possible to the dark-to-light color change in
the HRT reﬂectance image in order to deﬁne the
margin of the ONH [12], but for the present study we
ensured that the contour line was placed on stable rim
tissue on top of the ring of Elschnig [27], which is often
most discernable from the underside of the 3D image,
as a ridge circumscribing the ONH. With these
3D-based contour lines, the mean measured disk areas
for each of our subject groups were very nearly cen-
tered within the norms provided by Heidelberg Engi-
neering on the HRT II printout. Thus, with one
exception, all analyses of HRT values are based on the
contour lines drawn according to the more recent set of
criteria, which are intended to place the contour line
exactly at the disk margin, rather than slightly within it.
The one exception was made to assess the importance
(or lack of importance) of the precise contour
line placement for documenting between-group
Table 1 Demographic data for each of the subject groups
Amenorrheic subjects
40–69 years old
Amenorrheic subjects
51–69 years old
Not
amenorrheic,
no breast
cancer history
n =1 9
Anastrozole
n =2 0
Tamoxifen
n =3 4
Control,
no breast
cancer history
n =3 2
Anastrozole
n =1 8
Tamoxifen
n =2 5
Control,
no breast
cancer history
n =2 9
Age
(years)
58.2
(SD = 6.8)
54.5
(SD = 5.2)
57.2
(SD = 6.0)
59.6
(SD = 5.4)
56.5
(SD = 4.7)
58.2
(SD = 5.1)
48.0
(SD = 3.3)
IOP
(mmHg)
15.7
(SD = 2.9)
15.5
(SD = 2.3)
15.6
(SD = 2.9)
15.7
(SD = 3.0)
15.5
(SD = 2.5)
15.7
(SD = 3.0)
15.5
(SD = 2.3)
Duration of
medication
use (years)
1.07
(SD = 0.45)
1.31
(SD = 0.49)
0 1.09
(SD = 0.47
1.36
(SD = 0.48)
00
IOPs are from subjects’ test eyes only
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123differences. Thus, we conclude the Results section by
brieﬂy reporting the results of analyses based on data
obtained using the earlier contour-line placement cri-
teria.
Eyes were considered to have usable HRT data only
if the average standard deviation for the height of each
pixel in the 3 HRT scans did not exceed 50 lm, since
average topographic standard deviation values above
50 lm are considered by Heidelberg Engineering to
signify ‘‘low image quality’’ [28]. Image quality was
equally good for each subject group. The mean aver-
age-topographic-standard-deviation for each of the
three amenorrheic subject groups ranged from 20 to 22
(SD = 7–8) lm for all eligible subjects and also for
subjects older than 50 years. Among women still
experiencing menses, the mean was 23 (SD = 9) lm.
Although HRT scans were obtained for each sub-
ject’s 2 eyes, only one eye per subject was used for data
analysis for this paper. In this way, analyses could be
limited to eyes with 20/20 or better acuity for a maxi-
mal number of subjects. Thus, test eyes were deﬁned
initially using the following steps applied in order as
necessary: (a) the eye with the better acuity, even by 1
letter, than the fellow eye, (b) the eye with a lesser
degree of spherical equivalent refractive error than the
fellow eye, and (c) subject preference. In cases where
the initially designated test eye had an HRT average
topographic standard deviation value exceeding 50 lm,
the fellow eye became the test eye for analysis pur-
poses, but only if the fellow eye had 20/20 or better
acuity and an HRT average topographic standard
deviation value £50 lm. These are the same methods
we used previously to designate test eyes [12].
Data analyses
Comparisons of central tendency across more than two
subject groups were made using Kruskal–Wallis non-
parametric analyses of variance (ANOVAS) because
the distributions of some of the HRT indices were
signiﬁcantly non-Gaussian (1-sample Kolmogorov-
Smirnov test) in ways consistent with the literature
[29]. Similarly, post hoc comparisons between pairs of
groups were made using Mann–Whitney U tests.
Relations of HRT indices to age were evaluated for
signiﬁcance using Spearman rank-order coefﬁcients
because the strongest age trends were not linear. None
of the reported P-values have been adjusted for mul-
tiple comparisons, but the P-values required for sta-
tistical signiﬁcance of post-hoc tests as determined
using a step-down Bonferroni procedure [30] are pro-
vided in the legend to Table 2. All analyses were
conducted using SYSTAT 10.2 (Richmond, CA). All
P-values are for 2-sided tests.
Results
The optic cup volumes, maximum optic cup depths,
and cup/disk area ratios were each signiﬁcantly smaller
Table 2 ONH indices: between-group comparisons (subjects 40–69 years old)
ANOVA
(Kruskal–Wallis)
Anastrozole versus
tamoxifen
Tamoxifen versus
control
Anastrozole versus
control
Cup volume P = 0.021 P = 0.007 P = 0.052 P = 0.560
Maximum cup depth P = 0.016 P = 0.008 P = 0.036 P = 0.430
Mean cup depth P = 0.028 P = 0.011 P = 0.050 P = 0.645
Cup area P = 0.074 P = 0.028 P = 0.106 P = 0.612
Cup/disk area ratio P = 0.030 P = 0.013 P = 0.045 P = 0.763
Cup shape P = 0.593 P = 0.325 P = 0.797 P = 0.429
Rim area P = 0.115 P = 0.173 P = 0.053 P = 0.492
Rim volume P = 0.084 P = 0.059 P = 0.061 P = 0.940
Disk area P = 0.510 P = 0.474 P = 0.653 P = 0.232
Mean RNFL thickness P = 0.718 P = 0.654 P = 0.438 P = 0.735
RNFL cross sectional area P = 0.562 P = 0.573 P = 0.287 P = 0.721
Height variation contour P = 0.617 P = 0.375 P = 0.893 P = 0.387
Left-most data column––P-values for the non-parametric ANOVAS (Kruskal–Wallis) across all three amenorrheic subject-groups
simultaneously. Comparisons based on the results for the larger contour circles (see Methods). Right 3 columns––unadjusted P-values
for the post hoc comparisons (Mann–Whitney U tests) between pairs of subject-groups. The top 6 rows of variables are for cup data,
the next 2 rows are for rim data, and the bottom 4 rows are for disk-margin data. The bold entries signify P-values that are considered
statistically signiﬁcant. For the ANOVAS, statistical signiﬁcance was considered to be p £ 0.05. For the post-hoc comparisons, a step-
down Bonferroni approach was used, so that the ﬁrst (i.e., the most signiﬁcant) comparison required a signiﬁcant ANOVA plus
P £ 0.05/3, the second most signiﬁcant comparison required a signiﬁcant ﬁrst comparison plus P £ 0.05/2, and the third most signiﬁcant
comparison required a signiﬁcant second comparison plus P £ 0.05. ‘‘RNFL’’ signiﬁes retinal nerve ﬁber layer thickness. The height
variation contour signiﬁes the maximal minus the minimal retinal nerve ﬁber layer thickness, as deﬁned in the text
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123for the tamoxifen users than for the anastrozole users.
In contrast, none of the comparisons between anas-
trozole users and control subjects approached signiﬁ-
cance for any cup dimension. Table 2 provides
P-values for the between-group comparisons for every
summary ONH index. The cup-volume results are
represented graphically as a function of age in Fig. 1,
which presents the data from the three groups of
amenorrheic subjects: tamoxifen users (ﬁlled symbols),
anastrozole users, (shaded symbols), and control sub-
jects (unﬁlled symbols).
The data in Fig. 1 indicate that among tamoxifen
users, cup volumes tended to be relatively small mainly
for those subjects older than about 50 years. Indeed,
cup volumes decreased signiﬁcantly with age (Spear-
man r = –0.41, P = 0.018) among tamoxifen users.
However, a correlational analysis would necessarily
reduce or obscure the signiﬁcance of any age-related
change if such change occurred predominantly within a
narrow age range. Thus, although the corresponding
results for cup area (Spearman r = –0.33), maximum
cup depth (Spearman r = –0.30), and cup/disk area
ratio (Spearman r = –0.34) were each non-signiﬁcant
when assessed using correlations, the cup volumes, cup
areas, maximum cup depths and cup/disk area ratios
were each signiﬁcantly lower (P < .05) for subjects
older than 50 years compared to subjects 50 years and
younger when based on between-group comparisons of
central tendencies. An age cutoff at 51 rather than
50 years yielded the same result. For each of these 2
age cutoffs, the difference in cup volumes between the
older and younger tamoxifen users was highly signiﬁ-
cant (p £ .005).
Among control subjects and anastrozole users, there
were not enough younger subjects to make meaningful
comparisons between these same 2 age classes. How-
ever, we also tested an additional group of women
without breast cancer histories, comprised of subjects
who met all the same eligibility criteria as the control
group, except for the absence of menses. None of the
ONH indices differed signiﬁcantly between the amen-
orrheic control group (32 women with an average age
of 57.2 years) and this additional group (19 women
with an average age of 48.0 years), and there was no
suggestion of any differences in the cup indices spe-
ciﬁcally. For example, the median cup volume equaled
0.077 mm
3 for the 32 control subjects and 0.076 mm
3
for the 19 subjects still experiencing menses. Similarly,
the median cup/disk area ratio equaled 0.20 for the 32
control subjects and 0.21 for these 19 additional sub-
jects. Among the 32 control subjects themselves, cup
volume was not correlated with age (Spearman r =–
0.08). Among anastrozole users, Spearman r = 0.27
(P = 0.255), but the regression line relating cup volume
to age accounted for only 5% of the total variance, and
for only 2% when the calculation was restricted to
subjects older than 50 years.
Because cup dimensions varied appreciably with age
only for tamoxifen users, and because this variation
appeared to be quite marked at about age 50 years, we
recomputed the between-group comparisons of all the
ONH indices for subjects older than 50 years. (None of
the 19 women still experiencing menses were included
in any of these comparisons). The results are shown in
Table 3. As expected, all of the between-group differ-
ences that were signiﬁcant when the data were com-
pared for all subjects remained signiﬁcant when the
data were compared for only the older subjects, and
many of the comparisons between tamoxifen users and
control subjects became signiﬁcant (e.g., for cup vol-
ume). In addition, rim volumes (i.e., the volume above
and outside the cup but within the disk) now differed
signiﬁcantly between groups when compared for all
three groups simultaneously, but not when compared
for any two groups on subsequent post hoc analysis.
Had we used a less conservative means of comparison
(a parametric ANOVA followed by Tukey’s HSD
test), the rim volumes of the tamoxifen users would
have been considered to be signiﬁcantly larger than
the rim volumes of the anastrozole users and also
than the rim volumes of the control users. This is
probably the appropriate interpretation, since rim
volumes, unlike cup volumes, were fairly normally
distributed, allowing the use of parametric statistics.
0.0
0.1
0.2
0.3
0.4
40 50 60 70
AGE (years)
CUP VOLUME (cubic mm)
Fig. 1 Graph of cup volume versus age for all amenorrheic
subjects. Filled circles represent tamoxifen users, shaded circles
represent anastrozole users, and unﬁlled circles represent control
subjects
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123Table 4 presents the means and standard errors of
the mean, along with the corresponding medians, for
every ONH index for each of the three groups of
subjects restricted to women older than 50 years. Note
that the means and medians for many ONH indices
(e.g., rim volume) were similar within groups, but that
for some ONH indices (e.g., cup volume), means and
medians were dissimilar, signifying a skewed distribu-
tion. Thus, Figs. 2–6 present between-group compari-
sons of medians with interquartile intervals plus overall
ranges for cup volume (Fig. 2), cup area (Fig. 3),
maximum cup depth (Fig. 4), cup/disk area ratio
(Fig. 5), and rim volume (Fig. 6), in all cases for
subjects older than 50 years. Although the cup areas of
the tamoxifen users were not signiﬁcantly smaller than
those of the control subjects, their cup/disk ratios were
signiﬁcantly lower, probably because a major source of
anatomic variability unrelated to tamoxifen use now
was factored out.
When the between-group comparisons of the ONH
indices were further restricted by excluding tamoxifen
and anastrozole users using these medications for less
than 1 year, every comparison that was signiﬁcant
(bold numerical entries in Table 3) remained signiﬁ-
cant. In addition, the duration of medication use was
observed to matter little or not at all for the
Table 3 ONH indices: between-group comparisons (subjects 51–69 years old)
ANOVA
(Kruskal–Wallis)
Anastrozole versus
tamoxifen
Tamoxifen versus
control
Anastrozole versus
control
Cup volume P = 0.006 P = 0.003 P = 0.019 P = 0.330
Maximum cup depth P = 0.007 P = 0.005 P = 0.014 P = 0.309
Mean cup depth P = 0.016 P = 0.007 P = 0.038 P = 0.463
Cup area P = 0.025 P = 0.009 P = 0.051 P = 0.431
Cup/disk area ratio P = 0.011 P = 0.005 P = 0.020 P = 0.540
Cup shape P = 0.340 P = 0.146 P = 0.400 P = 0.463
Rim area P = 0.113 P = 0.161 P = 0.049 P = 0.511
Rim volume P = 0.030 P = 0.018 P = 0.035 P = 0.678
Disk area P = 0.435 P = 0.301 P = 0.883 P = 0.217
Mean RNFL thickness P = 0.542 P = 0.350 P = 0.336 P = 1.000
RNFL cross sectional area P = 0.482 P = 0.369 P = 0.259 P = 0.878
Height variation
contour
P = 0.341 P = 0.160 P = 0.775 P = 0.242
Same as Table 2, except based on data from subjects older than 50 years)
Table 4 ONH indices: means
and standard errors of the
mean, and medians (subjects
51–69 years old)
Anastrozole n = 18 Tamoxifen n = 25 Control n =2 9
Cup volume (mm
3) 0.107 ± 0.017 0.043 ± 0.015 0.090 ± 0.017
0.104 0.012 0.073
Maximum cup depth (mm) 0.611 ± 0.047 0.423 ± 0.040 0.559 ± 0.040
0.591 0.378 0.594
Mean cup depth (mm) 0.207 ± 0.017 0.145 ± 0.014 0.189 ± 0.014
0.206 0.130 0.198
Cup area (mm
2) 0.476 ± 0.059 0.275 ± 0.050 0.423 ± 0.057
0.523 0.139 0.385
Cup/disk area ratio 0.207 ± 0.022 0.123 ± 0.021 0.193 ± 0.022
0.229 0.079 0.192
Cup shape –0.229 ± 0.015 –0.199 ± 0.012 –0.219 ± 0.013
–0.229 –0.205 –0.210
Rim area (mm
2) 1.724 ± 0.066 1.895 ± 0.071 1.697 ± 0.061
1.797 1.867 1.732
Rim volume (mm
3) 0.453 ± 0.025 0.593 ± 0.042 0.475 ± 0.028
0.461 0.580 0.506
Disk area (mm
2) 2.200 ± 0.094 2.169 ± 0.074 2.120 ± 0.067
2.316 2.156 2.154
Mean RNFL thickness (mm) 0.245 ± 0.010 0.264 ± 0.014 0.246 ± 0.008
0.246 0.262 0.242
RNFL cross sectional area (mm
2) 1.281 ± 0.059 1.366 ± 0.014 1.266 ± 0.049
1.282 1.335 0.242
Height variation contour (mm) 0.359 ± 0.019 0.401 ± 0.019 0.383 ± 0.015
0.375 0.388 0.391
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123anastrozole users. For instance, the regression line
relating cup volume to the duration of anastrozole use
accounted for only 5% of the total cup-volume vari-
ance among all 20 anastrozole users, and for only 4%
when the calculation was restricted to the 18 anas-
trozole users older than 50 years. These several sets of
results indicate that the cup differences between the
tamoxifen and anastrozole groups did not occur
because the anastrozole users had experienced too
short a period of medication use.
The bottom 4 indices listed in Tables 2–4 represent
biomorphometric assessments at the disk margin alone.
These are: (1) disk area, (2) mean retinal nerve ﬁber
layer (RNFL) thickness, (3) RNFL cross-sectional
area, and (4) the height variation contour, calculated as
the maximal minus the minimal RNFL thickness along
the contour line. None of these indices differed sig-
niﬁcantly between groups, although there was some
suggestion of greater RNFL thickness for the tamoxi-
fen users (see Table 4).
As stated in the Methods section, we also conducted
analyses using the ONH indices derived from contour
lines placed slightly interior to the anatomic disk
0.0
0.1
0.2
0.3
0.4
CUP VOLUME (cubic mm)
TAMOXIFEN CONTROL ANASTROZOLE
Fig. 2 Box plot of cup volume for women older than 50 years for
each of the three amenorrheic subject groups. For each group,
the horizontal line inside the box represents that group’s median
value. The bottom and top of the box represent the upper and
lower hinges, respectively, i.e., the ﬁrst and third quartiles
between which lie 50% of all the values. The whiskers represent
the range of values that fall within a distance D from the hinges,
where D equals 1.5 times the inter-quartile range. Asterisks
represent individual points that fall between a distance of D and
2D from the hinges. Open circles represent individual points that
are more distant outliers
0.0
0.5
1.0
1.5
CUP AREA (square mm)
TAMOXIFEN CONTROL ANASTROZOLE
Fig. 3 Same as Fig. 2, except that box plots are for cup areas
0.0
0.2
0.4
0.6
0.8
1.0
MAXIMUM CUP DEPTH (mm)
TAMOXIFEN CONTROL ANASTROZOLE
Fig. 4 Same as Fig. 2, except that box plots are for maximum
cup depths
0.0
0.1
0.2
0.3
0.4
0.5
CUP/DISK AREA RATIO
TAMOXIFEN CONTROL ANASTROZOLE
Fig. 5 Same as Fig. 2, except that box plots are for cup/disk area
ratios
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123margin rather than exactly at the disk margin. Every
statistically signiﬁcant result concerning the cup
remained signiﬁcant when based on the smaller con-
tours. Conversely, whereas some of the cup-area
comparisons involving tamoxifen users were not
statistically signiﬁcant when based on the larger con-
tours (see Tables 2, 3), every corresponding compari-
son became signiﬁcant when based on the smaller
contours. In particular, the cup-area values for the
older tamoxifen users (>50 years) became signiﬁcantly
lower than the cup-area values for the older control
subjects (>50 years), presumably because using the
smaller contours enhanced the importance of effects
occurring predominantly within the interior of the cup.
Discussion
Because tamoxifen users and anastrozole users share
similar medical histories, the results indicate that
tamoxifen often leads to reductions of optic-cup size
among middle-aged women older than about 50 years.
Any effects of anastrozole at the ONH remain un-
proven, and if they exist at all, they are probably minor
and opposite to the effects of tamoxifen. In contrast to
tamoxifen [9, 10], there seem to be no reports in the
peer-reviewed literature concerning any visual or
ocular side effects of anastrozole. One study has found
that anastrozole can cause regression of breast cancer
metastases within the choroid [31].
Because all of the women in this study met a rig-
orous set of criteria for excellent ocular health, any
cup-size changes presumably would be designated as
subclinical. Data from several reports suggest that the
color vision of tamoxifen users is often altered [10, 19,
20], although such alterations either are subtle or can
be revealed only under specialized laboratory condi-
tions, and there is no evidence that color vision chan-
ges are caused by effects occurring at the ONH. A
recent survey found that about 13% of tamoxifen users
reported experiencing vision changes that they attrib-
uted to tamoxifen [32], but the nature of these pur-
ported changes was not speciﬁed, nor were the
subjects’ reports related to the results of any eye
examination. Nevertheless, the subjects reporting vi-
sion changes had signiﬁcantly higher serum levels of
tamoxifen and a potent tamoxifen metabolite
(N-DMT) than did the women not reporting these
changes [32]. In contrast, reports of well-known side
effects associated with tamoxifen use, such as hot ﬂa-
shes and vaginal dryness, were not related signiﬁcantly
to these same serum levels [32]. Cases of tamoxifen-
induced optic neuropathy have been described in the
literature [12, 33–38], but such cases usually are con-
sidered rare [9, 10, 38]. Perhaps tamoxifen users
sometimes experience a degree of optic neuropathy
that would not be detected or conﬁrmed on a pre-
senting eye examination owing to the wide range of
normal cup appearances. If so, the results of this study
point to a potential new application for intraocular
imaging devices such as the HRT, which provides
spatial resolution at the ONH on the order of tens of
microns and is designed to detect longitudinal change
[39]. Several types of high-resolution intraocular
imaging device are now available clinically [39], and
they allow high-resolution biomorphometric data to be
collected in ways that are non-invasive and not intim-
idating to patients. The ease of data collection with
these devices may allow patients who report tamoxi-
fen-related vision change to be evaluated before and
after cessation of tamoxifen use, and also after any
rechallenge. Until this is done, and then only if changes
in vision are shown to correspond to anatomical
changes, might it be justiﬁed for the type of results
described in this study to direct therapy. Presently, the
only assured clinical application is to alert ophthal-
mologists and neurologists that assessment of the ONH
for conditions such as glaucoma or optic neuritis may
be complicated by the use of tamoxifen.
A human-subjects study such as ours cannot deﬁni-
tively identify the mechanism(s) by which tamoxifen
may reduce optic-cup size in vivo. Nevertheless, there
is evidence to suggest that tamoxifen might reduce cup
size via astrocytic swelling. First, tamoxifen is a potent
blocker of swelling- (or ‘‘volume-’’) activated chloride
channels for astrocytes assessed in culture [16, 40], and
astrocytes are abundant in the optic cup [18, 41]. Sec-
ond, although astrocytes are present in the RNFL [17,
0.0
0.2
0.4
0.6
0.8
1.0
1.2
RIM VOLUME (cubic mm)
TAMOXIFEN CONTROL ANASTROZOLE
Fig. 6 Same as Fig. 2, except that box plots are for rim volumes
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12341], they comprise proportionally more of the neural
volume as the cup is descended [41], and astrocytes
along with ganglion cell axons are abundant at the base
of the cup and also within the sides [42]. However, if
the ganglion cell axons increased in volume, one would
expect more visual dysfunction than is observed. In
addition, there is evidence that tamoxifen-induced
development of posterior subcapsular cataracts [10]
may involve the blockage of volume-activated chloride
channels [43], and that the utility of high-dose tamox-
ifen as salvage therapy for astrocytomas [44] may de-
pend partly on the ability of tamoxifen to cause
astrocytic swelling [45]. Based on photographic
assessment of the ONH and retina by a neuro-oph-
thalmologist (author JF), there did not appear to be
any difference in the vasculature of the three subject
groups that would have led to the between-group cup
differences quantiﬁed in this study and also observed in
the ONH photographs when examined for groups of
subjects rather than for isolated subjects.
The presence of a steep reduction of cup size with
age at about 50–51 years among the tamoxifen users
suggests that any ability of tamoxifen to reduce cup
size, by whatever means, depends on the absence or
near absence of natural female hormones, given that
the median age of natural menopause is 51 years [25]
and given that tamoxifen elevates the estrogen levels of
pre-menopausal women [46]. Hormone replacement
therapy might, in principle, prevent or alleviate
tamoxifen-induced reductions in cup size, but hormone
replacement is generally contraindicated for breast
cancer survivors, especially for women who have had
hormone-receptor-positive tumors [47] (although di-
verse opinions exist [48]). Hormonal reduction by it-
self, whether occurring naturally or induced by
anastrozole, does not appear to result in cup-size
reductions of nearly the magnitude or the frequency
inferred for the older tamoxifen users, at least not for
the age range that we investigated. The presence of
small cups among the tamoxifen users probably did not
result from selectively low IOP levels, since the mea-
sured IOPs for each subject group were quite similar,
differing by no more than 0.2 mmHg on average. Be-
cause the presence of small cups among tamoxifen
users appeared to be unaccompanied by corresponding
signiﬁcant effects at the disk margin, the effects of
tamoxifen on the ONH may be regarded as predomi-
nantly localized to the cup.
For this study, we found no evidence of any age-
related change of ONH indices for healthy women not
using hormonally acting medications. However, a
recent study of hundreds of subjects has documented
the presence of ONH differences between healthy men
and women older than 65 years [49]. In that study,
several ONH indices were found to differ signiﬁcantly
between men and women, but the greatest percentage
difference was for cup area, which averaged about 14%
smaller for women than for men [49]. There is separate
evidence that cup areas can depend slightly on the
phase of the natural menstrual cycle [50]. These 2 sets
of results along with our own results suggest that fur-
ther studies be conducted to elucidate the effects of
hormonally acting medications on the ONH. Such
studies should include elderly women using tamoxifen,
if possible, since elderly women have higher circulating
levels of tamoxifen than do younger women [51].
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